Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma

Table 1 Clinicopathological characteristics of 429 ICC patients

	No. of cases	Total No. of cases	Percentage (%)
Gender		429
Male	301		70.2
Female	128		29.8
Age (yr)		429
< 53	220		51.3
≥ 53	209		48.7
Choledocholithiasis		429
No	383		89.3
Yes	46		10.7
Pathology T		429
T1	11		2.5
T2	159		37.1
T3	112		26.1
T4	147		34.3
Pathology N		429
N0	341		79.5
N1	88		20.5
Pathology M		429
M0	408		95.1
M1	21		4.9
Pathology stage		429
I	11		2.5
II	126		29.4
III	133		31.0
IV	159		37.1
Maximum tumor diameter (cm)		429
≤ 5	145		33.8
> 5, ≤ 10	186		43.4
> 10	76		17.7
Diffuse type	22		5.1
Macroscopic satellite lesions		429
No	330		76.9
≤ 3	40		9.3
> 3	59		13.8
Macroscopic tumor thrombi		429
No	382		89.0
In blood vessel	32		7.5
In bile duct	10		2.3
In both	5		1.2
Serum HBsAg and HBcAb		427
HBsAg (+)	198		46.4
HBsAg (-) and HBcAb (+)	60		14.0
HBsAg (-) and HBcAb (-)	169		39.6
Serum AFP ( μg/L)		422
No	332		78.7
> 20, ≤ 1000	70		16.6
> 1000	20		4.7
Serum CEA ( μg/L)		420
No	370		88.1
> 10, ≤ 100	36		8.6
> 100	14		3.3
Serum CA19-9 (U/mL)		421
No	179		42.5
> 37, ≤ 507	143		34.0
> 507	99		23.5

ICC: Intrahepatic cholangiocarcinoma; AFP: α-fetoprotein; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9.